Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription

Articles published in J Gastroenterol Hepatol

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    November 2021
  1. GAZELAKIS K, Mendis S, Wang S, Wong S, et al
    Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
    J Gastroenterol Hepatol. 2021 Nov 22. doi: 10.1111/jgh.15735.

    October 2021
  2. OGAWA E, Kawano A, Ooho A, Furusyo N, et al
    Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection.
    J Gastroenterol Hepatol. 2021 Oct 7. doi: 10.1111/jgh.15703.
    PubMed     Abstract available

    August 2021
  3. UENO M, Mano T, Kayahara T, Mizuno M, et al
    Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding: It's time to step forward.
    J Gastroenterol Hepatol. 2021 Aug 8. doi: 10.1111/jgh.15652.

    July 2021
  4. ATTEBERRY P, Biederman B, Jesudian A, Lucero C, et al
    Mortality, Sepsis, and Organ Failure in Hospitalized Patients with Cirrhosis Vary by Type of Infection.
    J Gastroenterol Hepatol. 2021 Jul 22. doi: 10.1111/jgh.15633.
    PubMed     Abstract available

  5. KRIGE J, Jonas E, Spence R, Bernon M, et al
    Letter to the editor: The complexities of predicting outcome in cirrhotic patients with acute variceal bleeding.
    J Gastroenterol Hepatol. 2021 Jul 12. doi: 10.1111/jgh.15622.

  6. ITO T, Hanafusa N, Soneda N, Isoai A, et al
    Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) against cirrhotic ascites in comparison with malignancy-related ascites.
    J Gastroenterol Hepatol. 2021 Jul 11. doi: 10.1111/jgh.15620.
    PubMed     Abstract available

    June 2021
  7. ZULLO A, Soncini M, Bucci C, Marmo R, et al
    Clinical outcomes in cirrhotics with variceal or nonvariceal gastrointestinal bleeding: a prospective, multicenter cohort study.
    J Gastroenterol Hepatol. 2021 Jun 29. doi: 10.1111/jgh.15601.
    PubMed     Abstract available

  8. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    PubMed     Abstract available

  9. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    PubMed     Abstract available

  10. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    PubMed     Abstract available

    May 2021
  11. YANG C, Liu J, Shi Q, Huang S, et al
    Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    J Gastroenterol Hepatol. 2021 May 11. doi: 10.1111/jgh.15543.
    PubMed     Abstract available

  12. HSU WF, Tsai PC, Chen CY, Tseng KC, et al
    Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (T-COACH).
    J Gastroenterol Hepatol. 2021 May 7. doi: 10.1111/jgh.15538.
    PubMed     Abstract available

    March 2021
  13. SHARMA C, Cococcia S, Ellis N, Parkes J, et al
    Systematic review: Accuracy of The Enhanced Liver Fibrosis Test for diagnosing advanced liver fibrosis and cirrhosis.
    J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482.
    PubMed     Abstract available

  14. WONG GL, Yuen PC, Ma AJ, Chan AW, et al
    Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis.
    J Gastroenterol Hepatol. 2021;36:543-550.
    PubMed     Abstract available

    February 2021
  15. WEST J, Gow PJ, Testro A, Chapman B, et al
    Exercise physiology in cirrhosis and the potential benefits of exercise interventions - a review.
    J Gastroenterol Hepatol. 2021 Feb 27. doi: 10.1111/jgh.15474.
    PubMed     Abstract available

  16. KIM JH, Park SW, Jung JH, Park DH, et al
    Bedside Risk-Scoring Model for Predicting 6-Week Mortality in Cirrhotic Patients Undergoing Endoscopic Band Ligation for Acute Variceal Bleeding.
    J Gastroenterol Hepatol. 2021 Feb 4. doi: 10.1111/jgh.15426.
    PubMed     Abstract available

    January 2021
  17. YI F, Guo X, Wang L, Xu X, et al
    Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume.
    J Gastroenterol Hepatol. 2021 Jan 3. doi: 10.1111/jgh.15386.
    PubMed     Abstract available

  18. LUM JHM, Cheah MCC, Leow WQ, Wan WK, et al
    Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    J Gastroenterol Hepatol. 2021;36:257-261.
    PubMed     Abstract available

  19. TAKEMURA K, Takizawa E, Tamori A, Nakamae M, et al
    Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.
    J Gastroenterol Hepatol. 2021;36:217-224.
    PubMed     Abstract available

    December 2020
  20. TERRA C, Perez R
    Albumin for cirrhotic patients with infections unrelated to spontaneous bacterial peritonitis: A still no answered question.
    J Gastroenterol Hepatol. 2020;35:2290-2291.

    September 2020
  21. SANDI BB, Leao GS, de Mattos AA, de Mattos AZ, et al
    Long-term albumin administration in patients with cirrhosis and ascites: a meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2020 Sep 10. doi: 10.1111/jgh.15253.
    PubMed     Abstract available

  22. KOGISO T, Hashimoto E
    Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:1459-1460.

  23. CHEN TP, Lai M, Lin WY, Huang KC, et al
    Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study.
    J Gastroenterol Hepatol. 2020;35:1636-1643.
    PubMed     Abstract available

  24. YIP TC, Lee HW, Wong VW, Wong GL, et al
    Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
    J Gastroenterol Hepatol. 2020;35:1610-1618.
    PubMed     Abstract available

  25. POUSTCHI H, Majd Jabbari S, Merat S, Sharifi AH, et al
    The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
    J Gastroenterol Hepatol. 2020;35:1590-1594.
    PubMed     Abstract available

    August 2020
  26. EFE C, Torgutalp M, Henriksson I, Alalkim F, et al
    Extrahepatic autoimmune diseases in primary biliary cholangitis: prevalence, significance for clinical presentation and disease outcome.
    J Gastroenterol Hepatol. 2020 Aug 13. doi: 10.1111/jgh.15214.
    PubMed     Abstract available

    July 2020
  27. KHAN A, Maheshwari S, Gupta K, Naseem K, et al
    Rate, Reasons, Predictors, and Burden of Readmissions After Transjugular Intrahepatic Portosystemic Shunt Placement.
    J Gastroenterol Hepatol. 2020 Jul 25. doi: 10.1111/jgh.15194.
    PubMed     Abstract available

  28. ZAREBSKA-MICHALUK D, Jaroszewicz J, Buczynska I, Simon K, et al
    Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    J Gastroenterol Hepatol. 2020;35:1238-1246.
    PubMed     Abstract available

  29. FAN J, Wang Q, Luo B, Chen H, et al
    Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study.
    J Gastroenterol Hepatol. 2020;35:1215-1222.
    PubMed     Abstract available

    June 2020
  30. TAN EZ, Lai LL, Vethakkan SR, Nik Mustapha NR, et al
    Modest alcohol intake is not associated with significant hepatic steatosis nor more severe liver disease among patient with diabetes mellitus.
    J Gastroenterol Hepatol. 2020 Jun 24. doi: 10.1111/jgh.15160.
    PubMed     Abstract available

  31. BRAHMANIA M, Wiskar K, Walley KR, Celi LA, et al
    Lower household income is associated with an increased risk of hospital readmission in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2020 Jun 20. doi: 10.1111/jgh.15153.
    PubMed     Abstract available

  32. CAO DB, Wang YS
    Gastrointestinal: Intrahepatic periportal masses with uncommon computed tomography patterns: Hepatic extramedullary hematopoiesis of primary mylofibrosis.
    J Gastroenterol Hepatol. 2020 Jun 7. doi: 10.1111/jgh.15069.

  33. LEE HW, Ahn SH
    How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
    J Gastroenterol Hepatol. 2020;35:915-916.

  34. SHIN SK, Kim KO, Kim SH, Kwon OS, et al
    Exogenous 8-hydroxydeoxyguanosine ameliorates liver fibrosis through the inhibition of Rac1-NADPH oxidase signaling.
    J Gastroenterol Hepatol. 2020;35:1078-1087.
    PubMed     Abstract available

  35. NGUYEN TH, Wardell R, Chitturi S, Teoh N, et al
    When the liver gets stiff, the tough get moving.
    J Gastroenterol Hepatol. 2020;35:953-959.
    PubMed     Abstract available

  36. CHEN H, He C, Lv Y, Fan J, et al
    Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction.
    J Gastroenterol Hepatol. 2020;35:1049-1056.
    PubMed     Abstract available

    March 2020
  37. KIM JH, Kang SH, Lee M, Choi HS, et al
    Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
    J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
    PubMed     Abstract available

  38. YE L, Yu Y, Zhao Y
    Icariin-induced miR-875-5p attenuates epithelial-mesenchymal transition by targeting hedgehog signaling in liver fibrosis.
    J Gastroenterol Hepatol. 2020;35:482-491.
    PubMed     Abstract available

  39. JANG TY, Huang CI, Yeh ML, Liang PC, et al
    Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.
    J Gastroenterol Hepatol. 2020;35:473-481.
    PubMed     Abstract available

    February 2020
  40. DA SILVA FRANCO KMV, Vieira WB, Dias ARN, Falcao ASC, et al
    Doppler ultrasonography: A non-invasive method used to diagnose and follow up patients with chronic hepatitis C.
    J Gastroenterol Hepatol. 2020;35:314-319.
    PubMed     Abstract available

    January 2020
  41. PATERNOSTRO R, Kapzan L, Mandorfer M, Schwarzer R, et al
    Anemia and iron deficiency in compensated and decompensated cirrhosis: prevalence and impact on clinical outcomes.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14988.
    PubMed     Abstract available

  42. KOGISO T, Sagawa T, Kodama K, Taniai M, et al
    Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    J Gastroenterol Hepatol. 2020 Jan 23. doi: 10.1111/jgh.14989.
    PubMed     Abstract available

  43. TOYODA H, Atsukawa M, Watanabe T, Nakamuta M, et al
    Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-word setting: a large, multicenter study from Japan.
    J Gastroenterol Hepatol. 2020 Jan 16. doi: 10.1111/jgh.14982.
    PubMed     Abstract available

    December 2019
  44. ATSUKAWA M, Tsubota A, Takaguchi K, Toyoda H, et al
    Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    J Gastroenterol Hepatol. 2019 Dec 27. doi: 10.1111/jgh.14965.
    PubMed     Abstract available

  45. LI Y, Zhang Y, Chen T, Huang Y, et al
    Aldosterone induces activation of primary mice hepatic stellate cell and liver fibrosis via NLRP3 inflammasome.
    J Gastroenterol Hepatol. 2019 Dec 20. doi: 10.1111/jgh.14961.
    PubMed     Abstract available

  46. SOHN W, Kim JH, Cho JY
    Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotic patients using the International Club of Ascites-acute kidney injury criteria.
    J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1111/jgh.14871.
    PubMed     Abstract available

    November 2019
  47. JOSHITA S, Yamashita Y, Sugiura A, Uehara T, et al
    Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis.
    J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1111/jgh.14929.
    PubMed     Abstract available

  48. VARELAS LJ, Klinge MJ, Malik SM, Borhani AA, et al
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14920.
    PubMed     Abstract available

  49. FRENCH J, van der Mei I, Simpson S Jr, Ng J, et al
    Increasing Prevalence of Primary Biliary Cholangitis in Victoria, Australia.
    J Gastroenterol Hepatol. 2019 Nov 6. doi: 10.1111/jgh.14924.
    PubMed     Abstract available

  50. WU CK, Yang SC, Liang CM, Li YC, et al
    The role of antibiotics in upper gastrointestinal bleeding among cirrhotic patients without major complications after endoscopic hemostasis.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14873.
    PubMed     Abstract available

  51. TAKANO K, Saeki C, Oikawa T, Hidaka A, et al
    IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
    J Gastroenterol Hepatol. 2019 Nov 1. doi: 10.1111/jgh.14900.
    PubMed     Abstract available

    October 2019
  52. TOBARI M, Hashimoto E, Taniai M, Kodama K, et al
    The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis.
    J Gastroenterol Hepatol. 2019 Oct 9. doi: 10.1111/jgh.14867.
    PubMed     Abstract available

    September 2019
  53. HEUCKE N, Wuensch T, Mohr J, Kaffarnik M, et al
    Non-invasive structure-function assessment of the liver by 2D time-harmonic elastography and the dynamic Liver MAximum capacity (LiMAx) test.
    J Gastroenterol Hepatol. 2019;34:1611-1619.
    PubMed     Abstract available

  54. KANG MK, Park JG, Lee HJ, Kim MC, et al
    Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2019;34:1633-1640.
    PubMed     Abstract available

    August 2019
  55. SOBOTKA LA, Risaliti C, Hinton A, Michaels A, et al
    Management of Hepatic Hydrothorax and Effect on Length of Stay, Mortality, Cost, and 30-Day Hospital Readmission.
    J Gastroenterol Hepatol. 2019 Aug 23. doi: 10.1111/jgh.14842.
    PubMed     Abstract available

  56. WONG GL, Wong VW
    Non-alcoholic fatty liver disease in Asia: How is it different from the West?
    J Gastroenterol Hepatol. 2019;34:1267-1268.

  57. FUJII H, Imajo K, Yoneda M, Nakahara T, et al
    HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
    J Gastroenterol Hepatol. 2019;34:1390-1395.
    PubMed     Abstract available

  58. LAI LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, et al
    Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    J Gastroenterol Hepatol. 2019;34:1396-1403.
    PubMed     Abstract available

  59. TOMENO W, Imajo K, Kuwada Y, Ogawa Y, et al
    Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    J Gastroenterol Hepatol. 2019;34:1411-1416.
    PubMed     Abstract available

    July 2019
  60. IWAMOTO T, Maeda M, Saeki I, Hidaka I, et al
    Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    J Gastroenterol Hepatol. 2019;34:1231-1235.
    PubMed     Abstract available

  61. SAKAMOTO N, Suda G, Morikawa K, Ogawa K, et al
    Nutrition is often ignored in management of chronic liver diseases.
    J Gastroenterol Hepatol. 2019;34:1127-1128.

    June 2019
  62. LIU J, Shi Q, Xiao SP, Zhou C, et al
    Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage.
    J Gastroenterol Hepatol. 2019 Jun 20. doi: 10.1111/jgh.14761.
    PubMed     Abstract available

    March 2019
  63. YAMATO M, Sakai Y, Mochida H, Kawaguchi K, et al
    Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
    J Gastroenterol Hepatol. 2019 Mar 3. doi: 10.1111/jgh.14647.
    PubMed     Abstract available

  64. KUK N, Hodge A, Sun Y, Correia J, et al
    Human amnion epithelial cells and their soluble factors reduce liver fibrosis in a murine non-alcoholic steatohepatitis.
    J Gastroenterol Hepatol. 2019 Mar 1. doi: 10.1111/jgh.14643.
    PubMed     Abstract available

    January 2019
  65. KODAMA K, Kawaguchi T, Hyogo H, Nakajima T, et al
    Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1111/jgh.14608.
    PubMed     Abstract available

    December 2018
  66. TOBARI M, Hashimoto E, Taniai M, Ikarashi Y, et al
    Characteristics of nonalcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign.
    J Gastroenterol Hepatol. 2018 Dec 27. doi: 10.1111/jgh.14585.
    PubMed     Abstract available

    November 2018
  67. SUN Y, Lan X, Shao C, Wang T, et al
    Clinical Features of Idiopathic Portal Hypertension in China: A Retrospective Study of 338 Patients and Literature Review.
    J Gastroenterol Hepatol. 2018 Nov 21. doi: 10.1111/jgh.14552.
    PubMed     Abstract available

    October 2018
  68. CHEN S, Duan W, Li M, Li S, et al
    Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China.
    J Gastroenterol Hepatol. 2018 Oct 26. doi: 10.1111/jgh.14521.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.